Discussion of the "White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs".

The article discusses the adaptive dose-ranging designs. The author focuses on several aspects in pharmacology including the objectives of such trials, the decision criteria of each objective, the simulation method and accrual and long-term endpoints. Some recommendations regarding the clinical study of drug development is also presented.